首页 > 最新文献

Im Focus Onkologie最新文献

英文 中文
CINV: Wirksamkeit und Verträglichkeit der 5-HT3RAs insgesamt vergleichbar CINV: 5泰铢的有效性和耐受性
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4368-1
B. Kreutzkamp
{"title":"CINV: Wirksamkeit und Verträglichkeit der 5-HT3RAs insgesamt vergleichbar","authors":"B. Kreutzkamp","doi":"10.1007/s15015-018-4368-1","DOIUrl":"https://doi.org/10.1007/s15015-018-4368-1","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"31 1","pages":"58"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76133240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Checkpointinhibition plus Chemotherapie punktet beim SCLC SCLC的检查点抑制加化疗检查点
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4347-6
Judith Neumaier
{"title":"Checkpointinhibition plus Chemotherapie punktet beim SCLC","authors":"Judith Neumaier","doi":"10.1007/s15015-018-4347-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4347-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"438 3","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72594345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dritter CDK4/6-Inhibitor beim Mammakarzinom zugelassen 确实是美国疾病控制中心
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4385-0
K. Arnheim
{"title":"Dritter CDK4/6-Inhibitor beim Mammakarzinom zugelassen","authors":"K. Arnheim","doi":"10.1007/s15015-018-4385-0","DOIUrl":"https://doi.org/10.1007/s15015-018-4385-0","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"99 1","pages":"77 - 77"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90824476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entscheidungshilfe bei frühem Brustkrebs: Genomische Signaturen 早期乳腺癌决策助手:基因组特征
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4355-6
U. Nitz
{"title":"Entscheidungshilfe bei frühem Brustkrebs: Genomische Signaturen","authors":"U. Nitz","doi":"10.1007/s15015-018-4355-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4355-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"41 1","pages":"39-43"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77551069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
L-Thyroxin-Einnahme könnte Fatigue unter Chemotherapie fördern 服用l .潜伏素可以帮助化疗产生Fatigue
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4369-0
S. Christoph
{"title":"L-Thyroxin-Einnahme könnte Fatigue unter Chemotherapie fördern","authors":"S. Christoph","doi":"10.1007/s15015-018-4369-0","DOIUrl":"https://doi.org/10.1007/s15015-018-4369-0","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"3 1","pages":"59"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75127045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hoher Preis für Jodtherapie 碘酒便宜啊
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4357-4
Christian Behrend
{"title":"Hoher Preis für Jodtherapie","authors":"Christian Behrend","doi":"10.1007/s15015-018-4357-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4357-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"85 1","pages":"46"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76862062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
„Therapieassoziierte Mortalität praktisch eliminiert“ “准死亡”
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4339-6
Springer Medizin
{"title":"„Therapieassoziierte Mortalität praktisch eliminiert“","authors":"Springer Medizin","doi":"10.1007/s15015-018-4339-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4339-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"13 1","pages":"21-22"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77067422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wo investieren im Digital-Health-Markt? 数字交易市场在哪里?
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4381-4
Springer Medizin
{"title":"Wo investieren im Digital-Health-Markt?","authors":"Springer Medizin","doi":"10.1007/s15015-018-4381-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4381-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"24 1","pages":"75"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76147074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neue Optionen beim fortgeschrittenen Pankreaskarzinome 主控器的新选项
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4389-9
A. Bischoff
{"title":"Neue Optionen beim fortgeschrittenen Pankreaskarzinome","authors":"A. Bischoff","doi":"10.1007/s15015-018-4389-9","DOIUrl":"https://doi.org/10.1007/s15015-018-4389-9","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"90 1","pages":"78 - 78"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74528150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PARP-Inhibitoren halten Einzug in die Primärtherapie des fortgeschrittenen Ovarialkarzinoms parp抑制剂进入高级卵巢癌的初级治疗
Im Focus Onkologie
Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4356-5
F. Trillsch, N. Ditsch, S. Mahner
{"title":"PARP-Inhibitoren halten Einzug in die Primärtherapie des fortgeschrittenen Ovarialkarzinoms","authors":"F. Trillsch, N. Ditsch, S. Mahner","doi":"10.1007/s15015-018-4356-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4356-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"58 1","pages":"44-45"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77873194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Im Focus Onkologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1